Brian A. Jonas, MD, PhD, discusses novel biomarkers being explored in acute myeloid leukemia, including e-selectin, which Jonas believes is very promising.
Brian A. Jonas, MD, PhD, associate professor of medicine at UC Davis Health in Sacramento, California, discusses novel biomarkers being explored in acute myeloid leukemia (AML), including e-selectin, which Jonas believes is very promising.
According to Jonas, e-selectin is not yet among the biomarkers that aid decision-making in AML. Those biomarkers include genetic lesions, mutations, and chromosome abnormalities. Approved therapies exist for many of these alterations.
In the marrow microenvironment, e-selectin is a molecule that attaches to a ligand on a cell. E-selectin antagonists can bind to the cancer cells in the bone marrow and disrupt the mechanism of leukemic cell resistance. Jonas says this is a potential target for AML treatment.
Jonas says, in an interview, that a drug has been developed to target e-selectin in patients with AML. Recent results announced from the phase 1/2 of uproleselan (NCT02306291) showed improvement in overall survival and tolerable safety in the relapsed or refractory AML subgroup. The study is ongoing.
0:08 | When we think about the bottom records with the most data right now, I would think of things like the genetic lesions and the mutations, the chromosome abnormalities, as being the principal driving force in a lot of our decision-making in AML. This is true whether it's a decision about transplant, or a decision about therapy. But there are emerging market biomarkers out there, and one of them is e-selectin.
0:40 | E-selectin is involved in the bone marrow microenvironment where the hematopoietic stem cells, and the leukemia stem cells are located. It's a molecule, it's kind of like a sticky molecule that binds the selected ligand on the cell, and then it causes them to be retained or stay in that microenvironment. It’s involved in a lot of the interactions involved in a lot of intracellular pathways as well. It can be a potential target for AML treatment.